Your browser doesn't support javascript.
loading
Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation.
Zhang, Xiaoyu; Wang, Jiao; Liu, Yuqiu; Liu, Jie; Wang, Bei; Zhang, Qiuhui; Guan, Wei; Zhang, Huijuan; Xu, Li; Liu, Guiying; Zhang, Ping; He, Yi; Feng, Sizhou; Han, Mingzhe; Li, Changping; Jiang, Erlie; Xie, Wenjun.
Afiliação
  • Zhang X; Department of Hematopoietic Stem Cell Transplantation, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Unio
  • Wang J; Department of Public Health, Tianjin Medical University, 288 Nanjing Road, Tianjin, 300052, China.
  • Liu Y; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Liu J; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Wang B; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Zhang Q; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Guan W; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Zhang H; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Xu L; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Liu G; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
  • Zhang P; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.
  • He Y; Department of Hematopoietic Stem Cell Transplantation, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Unio
  • Feng S; Department of Hematopoietic Stem Cell Transplantation, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Unio
  • Han M; Department of Hematopoietic Stem Cell Transplantation, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Unio
  • Li C; Department of Public Health, Tianjin Medical University, 288 Nanjing Road, Tianjin, 300052, China.
  • Jiang E; Department of Hematopoietic Stem Cell Transplantation, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Unio
  • Xie W; Department of Nursing Care, State Key Laboratory of Experimental Hematology, Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, National Clinical , Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanj
J Transl Med ; 20(1): 596, 2022 12 14.
Article em En | MEDLINE | ID: mdl-36517908
ABSTRACT

BACKGROUND:

It has been well-documented that haplo-identical hematopoietic stem cell transplantation (HID-HSCT) can provide outcomes comparable to conventional matched sibling donor (MSD) HSCT, however, little is known about the effects on quality of life (QoL) in long-term survivors. This study is to investigate the differences in longitudinal performance of QoL between HID and MSD HSCT using a comprehensive assessment system.

METHODS:

This prospective study enrolled consecutive patients who had received allogenic-HSCT (allo-HSCT) between January 2018 and December 2019 in our center. All patients were informed to complete QoL questionnaires including the Mos 36-Item Short-Form Health Survey (SF-36) and the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT, version 4), using an online applet, before transplantation and at scheduled time points after transplantation. The linear mixed-effects model was used to analyze the variation trend of different dimensions of both SF-36 and FACT-BMT with different follow-up times.

RESULTS:

Of the 425 participants, recipients of HID and MSD who survived more than 1 year (n = 230) were included in the final analysis of QoL (median age [range] 36, [15, 66]). The 3 year overall survival (OS) of HID and MSD was 82.42% and 86.46%, respectively. QoL was assessed using both SF-36 and FACT-BMT and there was longitudinal recovery with clinical significance in the cohort. Compared to MSD-HSCT patients, HID-HSCT recipients demonstrated superior QoL performance in some subscales describing physical and mental wellness. Specifically, the difference in physical performance is more remarkable using FACT-BMT whereas that in mental wellness is more significant using SF36. In the subsequent stratified analysis, patients with a history of aGVHD or CMV reactivation demonstrated inferior QoL.

CONCLUSIONS:

Long-term survivors of HID HSCT achieved better QoL in some sub-scales compared to MSD HSCT. In addition, SF-36 and FACT-BMT demonstrated different performance thus combination of both improved capacity of the evaluation system.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article